Errata (DOI:10.1016/S1470-2045(07)70145-6);Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data

Lancet Oncology

Volumn 8, Issue 6, 2007, Pages 488-499

  Trivella, Marialena ^a   Pezzella, Francesco ^b   Pastorino, Ugo ^c   Harris, Adrian L ^d   Altman, Douglas G ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c National Tumour Institute   (Italy)

^d CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; ARTICLE; CANCER MORTALITY; CANCER STAGING; CLINICAL TRIAL; DENSITY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MICROVASCULATURE; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SYSTEMATIC REVIEW;

EID: 34249307226     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70220-6     Document Type: Erratum

References (84)

1. Dubinett S., and Elasshoff D. Assessing prognosis in non-small-cell lung cancer: Avenues to a more complete picture. J Clin Oncol 22 (2004) 1-3
2. Posther K., and Harpole D. The surgical management of lung cancer. Cancer Invest 24 (2006) 56-57
3. Altman D., and Riley R. Primer: and evidence-based approach to prognostic markers. Nat Clin Pract Oncol 2 (2005) 1-7
4. Altman D. Systematic reviews of evaluations of prognostic variables. BMJ 323 (2001) 224-228
5. Deeks J. Systematic reviews of published evidence: miracles or minefields?. Ann Oncol 9 (1998) 703-709
6. Altman D. Suboptimal analysis using 'optimal' cutpoints. Br J Cancer 78 (1998) 556-557
7. Altman D., Lausen B., Sauerbrei W., and Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Instit 86 (1994) 829-835
8. Begg C., and Berlin J. Publication Bias: a problem in interpreting medical data. J Royal Stat Soc 151 (1988) 419-463
9. Song F., Eastwood A., Gilbody S., et al. Publication and related bias. Health Tech Assess 4 (2000) 1-115
10. Shaheen N., Crosby M., Bozymski E., and Sandler R. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology 119 (2000) 333-338
11. Popat S., Matakidou A., and Houlston R. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22 (2003) 529-536
12. Kyzas P., Loizou K., and Ioannidis J. Selective reporting bias in cancer prognostic factor studies. J Natl Cancer Instit 97 (2005) 1043-1055
13. Riley R., Heney D., Jones D., et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 10 (2004) 4-12
14. Altman D., and Lyman G. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 52 (1998) 289-303
15. Altman D., Trivella M., Pezzella F., et al. Systematic review of multiple studies of prognosis: the feasibility of obtaining individual patient data. In: Balakrishnan N., Auget J.-L., Mesbah M., and Molenberghs G. (Eds). Advances in statistical methods for the health sciences: applications to cancer and AIDS studies, genome sequence analysis, and survival analysis (2007), Birkhäuser, Boston 3-18
16. Trivella M. Systematic reviews of prognostic factor studies. DPhil thesis, University of Oxford; 2006.
17. Stewart L., and Clarke M. Practical methodology of meta-analysis (overviews) using updated individual patient data. Stats Med 14 (1995) 2057-2079
18. Vermeulen P., Gasparini G., Fox S., et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 38 (2002) 1564-1579
19. Passalidou E., Trivella M., Singh N., et al. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer 86 (2002) 244-249
20. Vermeulen P., Gasparini G., Fox S., et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A (1996) 2474-2484
21. Weidner N., Semple J., Welch W., and Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. New Engl J Med 324 (1991) 1-8
22. Chalkley H. Method for the quantitative morphologic analysis of tissues. J Natl Cancer Instit 4 (1943) 47-53
23. Decaussin M., Sartelet H., Robert C., et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinoma (NSCLCs): correlation with angiogenesis and survival. J Pathol 188 (1999) 369-377
24. Cox G., Walker R., Andi A., et al. Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer 29 (2000) 169-177
25. Mattern J., Koomägi R., and Volm M. Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. International. J Oncol 6 (1995) 1059-1062
26. Dazzi C., Cariello A., Maioli P., et al. Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer. Lung Cancer 24 (1999) 81-88
27. Giatromanolaki A., Koukourakis M., O'Byrne K., et al. Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 179 (1996) 80-88
28. Pastorino U., Andreola S., Tagliabue E., et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 15 (1997) 1-8
29. Fontanini G., Lucchi M., Vignati S., et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Instit 89 (1997) 881-886
30. Harpole Jr. D., Richards W., Herndon J., and Sugarbaker D. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thoracic Surg 61 (1996) 1470-1476
31. Yamazaki K., Abe S., Takekawa H., et al. Tumour angiogenesis in human lung adenocarcinoma. Cancer 74 (1994) 2245-2250
32. Eerola A.-K., Soini Y., and Pääkkö P. Tumour infiltrating lymphocytes in relation to tumour angiogenesis, apoptosis and prognosis in patients with large cell lung carcinoma. Lung Cancer 26 (1999) 73-83
33. Apolinario R., van der Valk P., de Jong J., et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularisation in patients with radically resected non-small-cell lung cancer. J Clin Oncol 15 (1997) 2456-2466
34. Chandrachud L., Pendleton N., Chisholm D., et al. Relationship between vascularity, age and survival in non-small-cell lung cancer. Br J Cancer 76 (1997) 1367-1375
35. Giatromanolaki A., Koukourakis M., Theodosiou D., et al. Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. Clin Cancer Res 3 (1997) 2485-2492
36. Offersen B., Pfeiffer P., Hamilton-Dutoit S., and Overgaard J. Patterns of angiogenesis in nonsmall cell lung carcinoma. Cancer 91 (2001) 1500-1509
37. Royston P., Altman D., and Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 25 (2006) 127-141
38. Greatens T., Niehans G., Rubins J., et al. Do molecular markers predict survival in non-small-cell lung cancer?. Am J Resp Crit Care Med 157 (1998) 1093-1097
39. Deeks J., Altman D., and Bradburn M. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M., Davey-Smith G., and Altman D. (Eds). Systematic reviews in health case. Meta-analysis in context (2001), BMJ Books, London 285-312
40. Higgins J., Thompson S., Deeks J., and Altman D. Measuring inconsistency in meta-analysis. BMJ 327 (2003) 557-560
41. Duarte I., Bufkin B., Pennington M., et al. Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. J Thoracic Cardiovasc Surg 115 (1998) 652-659
42. Simon R., and Altman D. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69 (1994) 979-985
43. De Long E., Nelson C., Wong J., et al. Using observational data to estimate prognosis: an example using a coronary artery disease registry. Stat Med 20 (2001) 2505-2532
44. Hays D., Trock B., and Harris A. Assessing the clinical impact of prognostic factors: when is 'statistically significant' clinically useful?. Breast Cancer Res Treatment 52 (1998) 305-319
45. Kernan W., Feinstein A., and Brass L. A methodological appraisal of research on prognosis after transient ischemic attacks. Stroke 22 (1991) 1108-1116
46. Levine M., Browman G., Gent M., et al. When is a prognostic factor useful? A guide for the perplexed. J Clin Oncol 9 (1991) 348-356
47. Riley R., Abrams K., Sutton A., et al. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer 88 (2003) 1191-1198
48. Piedbois P., and Buyse M. Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol 22 (2004) 3839-3841
49. Riley R., Burchill S., Abrams K., et al. A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family. Eur J Cancer 39 (2003) 19-30
50. Duchateau L., Pignon J., Bijnens J., and Sylvester R. Individual patient-versus literature-based meta-analysis of survival data: time to event and event rate at a particular time can make a difference, an example based on head and neck cancer. Control Clin Trials 22 (2001) 538-547
51. Clarke M., Stewart L., and Bijnens L. Individual patient data meta-analyses in cancer. Br J Cancer 77 (1998) 2036-2044
52. Stewart L., and Parmar M. Meta-analysis of the literature or of individual patient data: is there a difference?. Lancet 341 (1993) 418-422
53. Jeng G., Scott J., and Burmeister L. A comparison of meta-analytic results using literature vs individual patient data. JAMA 274 (1995) 830-836
54. Look M., van Putten W., Duffy M., et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Instit 94 (2002) 116-128
55. Arnott S., Duncan W., Gignoux M., et al. Preoperative radiotherapy in esophaheal carcinoma: a meta-analysis using individual patient data. Int J Radiat Oncol Biol Phys 41 (1998) 579-583
56. Collaborative group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer-collaborative re-analysis of individual patient data from 53 epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease. Br J Cancer 87 (2002) 1234-1245
57. Malats N., Bustos A., Nascimento C., et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6 (2005) 678-686
58. Sterne J., Gavaghan D., and Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53 (2000) 1119-1129
59. Easterbrook P., Berlin J., Gopalan R., and Matthews D. Publication bias in clinical research. Lancet 337 (1991) 867-872
60. McShane L., Altman D., Sauerbrei W., et al. REporting recommendation for tumour MARKer prognostic studies (REMARK). Br J Cancer 93 (2005) 387-391
61. Goebell P., Groshen S., Schmitz-drager B., et al. The international bladder cancer bank: proposal for a new study concept. Urol Oncol 22 (2004) 277 Urologic Oncology: Seminars and Original Investigations 84.
62. Yano T., Tanikawa S., Fujie T., et al. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer 36 (2000) 601-609
63. Han H., Silverman J., Santucci T., et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 8 (2001) 72-79
64. Kawaguchi T., Yamamoto S., Kudoh S., et al. Tumour angiogenesis as a major prognostic factor in stage I lung adenocarcinoma. Anticancer Res 17 (1997) 3743-3746
65. Matsuyama K., Chiba Y., Sasaki M., et al. Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer. Ann Thorac Surg 65 (1998) 1405-1409
66. Lucchi M., Fontanini G., Mussi A., et al. Tumour angiogenesis and biologic markers in resected stage I NSCLC. Eur J Cardiothorac Surg 12 (1997) 535-541
67. Shijubo N., Kojima H., Nagata M., et al. Tumor angiogenesis of non-small cell lung cancer. Microsc Res Tech 60 (2003) 186-198
68. O'Byrne K., Koukourakis M., Giatromanolaki A., et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82 (2000) 1427-1432
69. Ohta Y., Tomita Y., Oda M., et al. Tumour angiogenesis and recurrence in stage I non-small cell lung cancer. Ann Thorac Surg 68 (1999) 1034-1038
70. Shibusa T., Shijubo N., and Abe S. Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res 4 (1998) 1483-1487
71. Hansen S., Grabau D., Rose C., et al. Angiogenesis in breast cancer: a comparative study of the observer variability of methods for determining microvessel density. Lab Invest 78 (1998) 1563-1573
72. Offersen B., Borre M., and Overgaard J. Quantification of angiogenesis as a prognostic marker in human carcinomas: a critical evaluation of histopathological methods for estimation of vascular density. Eur J Cancer 39 (2003) 881-890
73. Marson L., Kurian K., Miller W., and Dixon J. Reproducibility of microvessel counts in breast cancer specimens. Br J Cancer 81 (1999) 1088-1093
74. de Jong J., Van Diest P., and Baak J. Heterogeneity and reproducibility of microvessel counts in breast cancer. Lab Invest 73 (1995) 922-926
75. Fox S., Leek R., Weekes M., et al. Quantitation and prognostic value of breast cancer angiogenesis: comparisson of microvessel density, Chalkley count, and computer image analysis. J Pathol 177 (1995) 275-283
76. Martin L., Green B., Renshaw C., et al. Examining the technique of angiogenesis assessment in invasive breast cancer. Br J Cancer 76 (1997) 1046-1054
77. Offersen B., Borre M., Sørensen F., and Overgaad J. Comparison of methods of microvascular staining and quantification in prostate carcinoma: relevance to prognosis. APMIS 110 (2002) 185
78. Tanaka F., Otake Y., Yanagihara K., et al. Evaluation of angiogenesis in non-small cell lung cancer: Comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 7 (2001) 3410-3415
79. Meert A., Paesmans M., Martin B., et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 87 (2002) 694-701
80. Williamson P., Smith C.T., Hutton J., and Marson A. Aggregate data meta-analysis with time-to-event outcomes. Stat Med 21 (2002) 3337-3351
81. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med; 17: 2815-34.
82. Tudur C., Williamson P., Khan S., and Best L. The value of the aggregate data approach in meta-analysis with time-to-event outcomes. J Royal Stat Soc 164 (2001) 357-370
83. Duchateau L., Collette L., Sylvester R., and Pignon J.-P. Estimating a number of events from Kaplan-Meier curve for incorporation in a literature-based meta-analysis: what you don't see you can't get. Biometrics 56 (2000) 886-892
84. Blanchon F., Grivaux M., Asselain B., et al. 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol 7 (2006) 829-836